Alerts will be sent to your verified email
Verify Email
PANACEABIO
|
Panacea Biotec
|
Novartis
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
6.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
9.86 % | n/a | 2.7 % |
|
Financials
|
|||
|
5 yr Average ROE
|
36.5 % | 8.0 % | 6.83 % |
|
5yr average Equity Multiplier
|
0.36 | 2.72 | 1.3 |
|
5yr Average Asset Turnover Ratio
|
0.41 | 0.18 | 0.62 |
|
5yr Avg Net Profit Margin
|
26.1 % | 17.12 % | 8.7 % |
|
Price to Book
|
2.52 | 3.17 | 2.09 |
|
P/E
|
0.0 | 25.31 | 21.65 |
|
5yr Avg Cash Conversion Cycle
|
-170.26 Days | -23.33 Days | 186.56 Days |
|
Inventory Days
|
120.03 Days | 44.27 Days | 54.35 Days |
|
Days Receivable
|
42.2 Days | 38.18 Days | 189.93 Days |
|
Days Payable
|
325.14 Days | 124.28 Days | 75.78 Days |
|
5yr Average Interest Coverage Ratio
|
2.7 | 65.43 | 14.68 |
|
5yr Avg ROCE
|
-2.79 % | 5.91 % | 13.27 % |
|
5yr Avg Operating Profit Margin
|
-3.85 % | 15.15 % | 17.03 % |
|
5 yr average Debt to Equity
|
-0.69 | 0.0 | 0.11 |
|
5yr CAGR Net Profit
|
-43.68 % | 37.01 % | 4.24 % |
|
5yr Average Return on Assets
|
9.32 % | 3.13 % | 5.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
72.48 % | 70.68 % | 35.36 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-1.11 % | 0.0 | 0.9 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Panacea Biotec
|
Novartis
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Brand Wise Break-Up
|
Brand Wise Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|